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Abstract
Considerable epidemiologic evidence and plausible biobehavioral mechanisms suggest that
depression is an independent risk factor for diabetes. Moreover, reducing the elevated diabe-
tes risk of depressed individuals is imperative given that both conditions are leading causes of
death and disability. However, because no prior study has examined clinical diabetes out-
comes among depressed patients at risk for diabetes, the question of whether depression
treatment prevents or delays diabetes onset remains unanswered. Accordingly, we examined
the effect of a 12-month collaborative care program for late-life depression on 9-year diabetes
incidence among depressed, older adults initially free of diabetes. Participants were 119 pri-
mary care patients [M (SD) age: 67.2 (6.9) years, 41% African American] with a depressive
disorder but without diabetes enrolled at the Indiana sites of the Improving Mood-Promoting
Access to Collaborative Treatment (IMPACT) trial. Incident diabetes cases were defined as
diabetes diagnoses, positive laboratory values, or diabetes medication prescription, and were
identified using electronic medical record and Medicare/Medicaid data. Surprisingly, the rate
of incident diabetes in the collaborative care group was 37% (22/59) versus 28% (17/60) in
the usual care group. Even though the collaborative care group exhibited greater reductions in
depressive symptom severity (p = .024), unadjusted (HR = 1.29, 95% CI: 0.69–2.43, p = .428)
and adjusted (HR = 1.18, 95% CI: 0.61–2.29, p = .616) Cox proportional hazards models indi-
cated that the risk of incident diabetes did not differ between the treatment groups. Our novel
preliminary findings raise the possibility that depression treatment alone may be insufficient to
reduce the excess diabetes risk of depressed, older adults.
Introduction
Type 2 diabetes is a serious metabolic condition that is highly prevalent worldwide (9%) and
has substantial consequences for individuals and for society [1]. Depression, the leading cause
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of disability worldwide, affects 350 million people and therefore, is also highly prevalent [2].
Findings from prospective cohort studies indicate that depression is an independent risk factor
for diabetes, with risk ratios similar to well-established diabetes risk factors, including obesity,
smoking, and physical inactivity [3]. Additionally, plausible biological (e.g., hypothalamic-pit-
uitary-adrenal (HPA) axis hyperactivation, systemic inflammation) and behavioral (e.g., poor
diet, physical inactivity) mechanisms underlying the depression-to-diabetes relationship have
been identified [3]. A recent meta-analysis confirmed the elevated diabetes risk associated with
depression, concluding that depressed adults have a 60% greater risk of developing type 2 dia-
betes than their nondepressed counterparts [3].
Findings from a few small intervention studies targeting depressed individuals without diabe-
tes at baseline have shown that depression treatment improves a marker of prediabetes known
as insulin sensitivity, particularly among patients whose achieved depression remission [4–6].
Although these findings are promising, only intervention studies examining incident clinical
diabetes as an outcome can answer the key question of whether depression treatment prevents
or delays the onset of type 2 diabetes. If such a study yields positive results, depression treatment
could be pursued as a promising new approach for the primary prevention of diabetes. However,
even negative results would be quite informative, as they would imply an alternate approach to
reduce the risk for this highly prevalent chronic disease, for instance, comprehensive depression
care in conjunction with a lifestyle intervention to address well-established diabetes risk factors
(e.g., obesity). Despite the urgent need for addressing this key question, no prior study has exam-
ined incident clinical diabetes outcomes among depressed patients at risk for diabetes. Accord-
ingly, we conducted a preliminary study examining the effects of a 12-month collaborative care
program for late-life depression on the 9-year incidence of diabetes among depressed, older
adults initially free of diabetes.
Materials and methods
Participants
We conducted a 9-year follow-up study of the Improving Mood-Promoting Access to Collabo-
rative Treatment (IMPACT) trial, a multisite, randomized controlled trial that examined the
effectiveness of collaborative care for late-life depression among depressed, older primary care
patients (See [7] for detailed trial methods; ClinicalTrials.gov Identifier: NCT01561105; http://
clinicaltrials.gov/ct2/show/NCT01561105). To ascertain eligibility for the trial, patients under-
went a depression screen [8] and an eligibility interview [9]. Inclusion criteria for the IMPACT
trial were age60 years and a current major depressive disorder or dysthymia diagnosis,
while exclusion criteria were: a drinking problem [10], bipolar disorder/psychosis, currently in
psychiatric treatment, severe cognitive impairment [11], or at acute risk of suicide. Our follow-
up study was approved by the IUPUI Institutional Review Board and the Centers for Medicare
and Medicaid Services Privacy Board. Participants provided written informed consent to the
IMPACT procedures, and a waiver of consent was obtained to link electronic medical record
and Medicare/Medicaid data.
This study utilized data from the 235 participants enrolled at the Indiana sites of the IMPACT
trial, the only cohort for whom a unique set of resources–i.e., local electronic medical record data
(including death certificate data) linked with Medicare and Medicaid claims–were available.
Notably, this study utilized a local electronic medical record, the Regenstrief Medical Record Sys-
tem (RMRS) [12], which is one of the largest and longest operating electronic medical records
(earliest data from 1978). Using RMRS, we excluded 116 participants with prevalent diabetes at
baseline given that the focus of this study was new-onset diabetes. Prevalent diabetes was defined
as the presence of any of the following before the participant’s IMPACT enrollment date: (a) a
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diabetes diagnosis (ICD-9 code of 250); (b) a fasting glucose value 126 mg/dL; (c) an HbA1c
value 8.0%; or (d) a prescription for insulin or oral hypoglycemic medication. We used a cut
point of 8.0% for HbA1c rather than the American Diabetes Association’s cut point of 6.5%
[13] because more recently published guidelines [14] recommend the use of a higher cut point
(between 8–9%) for diagnosis among older adults who have comorbid medical conditions. We
chose the more conservative cut point in this range. The final sample consisted of 119 participants.
Treatment groups
In the IMPACT trial, participants were randomized to 12 months of the IMPACT collabora-
tive care program or usual primary care for depression. The IMPACT intervention has been
described in detail elsewhere [7, 15]. Participants in the IMPACT group worked with depres-
sion clinical specialists (DCSs) and their primary care providers to receive evidence-based
depression treatment according to a stepped care algorithm that varied intervention type and
intensity according to clinical needs and patient preference. Step 1 of the algorithm recom-
mended that patients begin antidepressant medication (usually a selective serotonin reuptake
inhibitor [SSRI]) or a course of Problem Solving Treatment in Primary Care (PST-PC) [16], a
brief cognitive-behavioral therapy. Patients who achieved remission followed a relapse preven-
tion plan developed by the DCS. Patients who did not respond in 8–12 weeks proceeded to
Step 2 of the algorithm, which consisted of augmenting Step 1 treatment with a second antide-
pressant or psychotherapy or switching to another antidepressant or psychotherapy. A psychi-
atric consultation was initiated for patients with persistent depression. Patients who had not
achieved remission after 6–10 additional weeks proceeded to Step 3, in which further medica-
tion changes, psychotherapy, hospitalization, or other mental health services were considered.
Patients in the usual care group were informed of their diagnosis, were encouraged to follow-
up with their primary care provider, and were followed for 12 months while they received ser-
vices that were part of usual care. Providers received a letter indicating that their patient has a
depressive disorder and was randomized to usual care.
Outcome measures
Depression symptom severity was assessed at baseline and 12 months using the 20 depression
items of the Symptom Checklist-90 (SCL-20) [15, 17]. The SCL-20 is a widely used outcome
measure in primary care trials [18–21]. The measure has demonstrated good internal consis-
tency in previous studies (Cronbach’s α = 0.84–0.86) [22, 23], as well as in the IMPACT sample
recruited from the Indiana sites (Cronbach’s α = 0.81 at baseline and 0.91 at 12 months). In
terms of validity, the SCL-20 and PHQ-9, which is an established depression measure, have been
found to be moderately correlated with one another (r = 0.54). In addition, a 50% reduction in
SCL-20 score has been shown to accurately identify 79% of patients who no longer met criteria
for MDD after 12 weeks of collaborative care, suggesting that this cut point is a good indicator of
change in depression status [24]. At 12 months, participants were also asked about psychother-
apy and antidepressants received during the trial. Incident diabetes cases were identified using
data from the RMRS, merged with claims data from Medicare and Medicaid. Incident diabetes
was defined as the first occurrence of any of the following between the participant’s IMPACT
enrollment date (1999–2001) and December 31, 2009: (a) diabetes diagnosis (ICD-9 code of
250); (b) a fasting glucose value 126 mg/dL; (c) an HbA1c value 8.0% or (d) a prescription
for insulin or oral hypoglycemic medication.
Depression treatment and diabetes risk
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Other variables
During the IMPACT baseline interview, patients were asked by trained lay interviewers about
demographic information (age, sex, race/ethnicity) and if they had been diagnosed or treated
for any of 10 common chronic medical problems in the preceding 3 years, including diabetes
and hypertension [15]. Data regarding baseline smoking status and BMI were obtained thr-
ough RMRS. Several indicators of smoking status were obtained, including any smoking diag-
noses, yes/no markers for current smoking status, and packs-per-day information. If any of
these indicators was positive, the participant received a code of ‘1’ (yes) on smoking status; oth-
erwise, the participant received a code of ‘0’ (no). Height and weight information was also
obtained from RMRS. BMI was calculated as weight in kilograms divided by the square of
height in meters (kg/m2). Participants who endorsed use of antidepressants in the 3 months
preceding the baseline interview received a code of ‘1’ (yes) on this variable; otherwise, partici-
pants received a code of ‘0’ (no).
Data analyses. Prior to conducting any hypothesis-testing analyses, chi-square tests (for
categorical variables) and independent samples t tests (for continuous variables) were con-
ducted to compare baseline characteristics between patients in the IMPACT and usual care
groups. Additionally, a Cohen’s d effect size was calculated to quantify the effect of the IMPACT
intervention on change in SCL-20 score. To test our primary hypothesis, Cox proportional haz-
ard regression models were constructed [25]. Cox models yield hazard ratios (HR) as the pri-
mary statistic. For this study, HRs estimated the relative likelihood of incident diabetes in the
IMPACT group versus control group. Patients were censored at their date of death or at the end
of the follow-up period (December 31, 2009). The primary Cox model included the randomiza-
tion status variable (IMPACT vs. usual care) as the only independent variable (no covariates).
To supplement these primary analysis, Kaplan-Meier survival curves were constructed to illus-
trate the time from enrollment to incident diabetes for each treatment group. A second Cox
model was constructed to include baseline age, sex, race/ethnicity, hypertension, smoking, and
BMI variables in addition to the randomization status variable (fully-adjusted analyses). Analy-
ses were performed using SAS statistical software, version 9.3 (SAS Institute, Cary, NC).
We conducted two sets of sensitivity analyses. First, reran Cox models after modifying our
incident diabetes definition. The alternative definitions were: (a) Any diagnosis: ICD-9 code of
250 (b); Any lab value: fasting glucose value 126 mg/dL OR HbA1c value 8.0%; (c) Any
diabetes medication: insulin or oral hypoglycemic medication. Second, we evaluated whether
the effect of collaborative depression treatment on diabetes was influenced by change in dep-
ressive symptoms during the trial. To do so, we created an SCL-20 change score (subtracting
the 12-month SCL-20 score from the baseline score) and added it to the unadjusted Cox
model that only included the randomization variable.
Results
Effect of the IMPACT intervention on depression outcomes and care
For our sample of 119 depressed, older adults who were free of diabetes at baseline (IMPACT:
n = 59, usual care: n = 60), independent sample t tests and chi-square tests revealed no group
differences in baseline age, sex, race/ethnicity, hypertension, and smoking (Table 1). However,
baseline BMI of the IMPACT group was higher than that of the usual care group (31.3 vs. 27.7
kg/m2; p = .024). At post-treatment (12 months), IMPACT patients exhibited greater reduc-
tions in SCL-20 score than usual care patients (p = .024), with a treatment effect size (d = 0.43)
in the medium range [26], suggesting greater improvement in depressive symptoms in the
IMPACT vs. usual care group. IMPACT patients were more likely than usual care patients to
Depression treatment and diabetes risk
PLOS ONE | https://doi.org/10.1371/journal.pone.0200248 August 23, 2018 4 / 11
have received psychotherapy (60% vs. 17%, p< .001) but not antidepressant medication (73%
vs. 57%, p = .064) during the trial (Table 1).
Effect of the IMPACT intervention on incident diabetes
Thirty-nine incident clinical diabetes cases (33%) were identified during the 9-year follow-up
period. The rate of incident diabetes in the IMPACT group was 37% (22/59) versus 28% in the
usual care group (17/60). Fig 1 displays the Kaplan-Meier survival curves illustrating the time
to incident diabetes for both treatment groups. A log-rank test indicated that there was no
group difference in incident diabetes (χ2 = .63, p = .427). Cox proportional hazards models
confirmed this finding. The unadjusted Cox model indicated that the risk of incident diabetes
did not differ between the collaborative care and usual care groups (HR = 1.29, 95% CI: 0.69–
2.43, p = .428), as did a Cox model adjusting for baseline age, sex, race/ethnicity, hypertension,
smoking, and BMI (HR = 1.18, 95% CI: 0.61–2.29, p = .616). In the adjusted model, only base-
line BMI predicted incident diabetes (HR = 1.05, 95% CI: 1.00–1.10, p = .027).
Sensitivity analyses
When we considered alternative definitions of incident diabetes, we found that there was some
variability in the rate of incident diabetes across these definitions, ranging from 11 events
(IMPACT = 7; usual care = 4) for the any medication outcome to 33 events (IMPACT = 19;
Table 1. Characteristics of participants by treatment group.
Characteristic Total
Sample
(N = 119)
IMPACT (n = 59) Usual Care (n = 60) p value
Baseline Demographic Factors
Age, mean (SD) 67.2 (6.9) 66.7 (6.5) 67.7 (7.3) .428
Male, % 23.5 20.3 26.7 .416
African-American, % 41.2 39.0 43.3 .630
Height (inches), mean (SD) Ϯ 64.6 (3.5) 64.2 (2.9) 65.0 (3.9) .221
Weight (pounds), mean (SD) Ϯ 175.1 (52.3) 183.3 (57.3) 167.0 (46.0) .089
Baseline Diabetes Risk Factors
Hypertension, % 73.1 72.9 73.3 .956
Smoker, % 36.1 32.2 40.0 .376
Body-Mass Index (kg/m2), mean (SD) 29.5 (8.5) 31.3 (9.6) 27.7 (7.0) .024
Baseline Depression Variables
MDD Only, % 12.6 11.9 13.3 .809
Dysthymia Only, % 33.6 33.9 33.3 .948
MDD and Dysthymia, % 53.8 54.2 53.3 .921
SCL-20 Score, mean (SD) (range: 0–4) 1.4 (0.5) 1.3 (0.6) 1.5 (0.5) .121
Antidepressant Use in Past 3 Months, % 50.4 52.5 48.3 .646
Depression Outcomes and Care Variables
SCL-20 Change, mean (SD) (N = 111) -0.13 (0.7) -0.3 (0.7) 0.0 (0.7) .024
Antidepressants during the trial, % 64.7 72.9 56.7 .064
Psychotherapy during the trial, % 37.8 59.3 16.7 < .001
Note. N = 119 except where indicated. Independent samples t tests were used to compare groups on age, body mass index, baseline SCL-20 score, and SCL-20 change.
All other group comparisons were made using chi-square tests. IMPACT = Improving Mood-Promoting Access to Collaborative Treatment. MDD = major depressive
disorder. SCL-20 = Symptom Checklist-20.
ϮSI conversions: To convert inches to centimeters, multiply by 2.54; To convert pounds to kilograms, multiply by 0.45
https://doi.org/10.1371/journal.pone.0200248.t001
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usual care = 14) for the any lab value outcome (see Table 2). There was also variability in the
treatment group differences in incident diabetes rates, with the lowest and highest treatment
group differences observed for the any medication outcome (IMPACT = 11.9%; usual
care = 6.7%) and the any diagnosis outcome (IMPACT = 22.0%; Usual Care = 11.7%), respec-
tively. Overall, collaborative care patients continued to have a similar risk of incident clinical
diabetes over nine years as usual care patients in unadjusted and fully-adjusted analyses (see
Table 2). Across all analyses, low event rates and large confidence intervals render interpreta-
tion difficult but suggest that the relationship between depression treatment and incident dia-
betes events does not vary by the type of incident diabetes definition used.
Finally, when we adjusted our primary analyses for change in depressive symptoms over
the 1-year intervention period, the hazard ratio for the treatment effect on incident diabetes
was not meaningfully altered (HR = 1.13, 95% CI: 0.59–2.18, p = .71), and change in depressive
symptoms did not predict incident diabetes (HR = 0.81, 95% CI: 0.49–1.34, p = .41).
Fig 1. Time to incident diabetes for IMPACT participants. Kaplan-Meier survival curves depicting time to incident diabetes (diabetes diagnosis, positive
laboratory value, or diabetes medication prescription) among depressed, older adults initially free of diabetes randomized to a 12-month collaborative care
program for depression (n = 59) or usual care (n = 60). IMPACT = Improving Mood-Promoting Access to Collaborative Treatment.
https://doi.org/10.1371/journal.pone.0200248.g001
Depression treatment and diabetes risk
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Discussion
Consistent with results of the parent IMPACT trial [7] and other depression trials involving
older adults [27], we found that depressed, older primary care patients randomized to collabo-
rative depression care exhibited significantly greater reductions in depressive symptoms than
those randomized to usual care. Despite these improvements, collaborative care patients had a
similar risk of incident clinical diabetes over nine years as usual care patients, even when alter-
native definitions of incident diabetes were considered.
Our preliminary findings do not align with results of prior intervention studies with non-dia-
betic samples, assessing insulin sensitivity outcomes. In two previous studies [4, 6], depressed,
non-diabetic patients who were given either tricyclic or SSRI antidepressants and who achieved
depression remission showed improved insulin sensitivity over a 5- to 8-week period. Of note, in
the larger of these two studies, depression remission was positively associated with only one of
three diabetes outcomes examined (insulin level after a glucose challenge, but not fasting insulin
or glucose levels). In another study [5], Okamura et al. reported that depressed, non-diabetic
patients who received either tricyclic or tetracyclic antidepressants showed improvement in insu-
lin sensitivity from pre- to post-treatment, as assessed by oral glucose tolerance tests. However,
because all three of these studies did not have a control group, it is possible that factors other
than the depression interventions were responsible for the observed improvements in insulin
sensitivity. In contrast, our results are consistent with those of Kauffman and colleagues [28],
who showed that 8 weeks of SSRI treatment did not produce improvement in insulin sensitivity,
as measured by oral glucose tolerance tests. Yet, even these results cannot easily be compared to
our results because of their dissimilar sample of 32 depressed and nondepressed, euglycemic
women of reproductive age. As is evident by these studies, there is a dearth of rigorous research
literature in which the effect of depression treatment on diabetes-related outcomes is examined
in samples of depressed patients initially free of diabetes.
There are at least two possible explanations for nonsignificantly elevated diabetes risk in the
IMPACT versus the usual care group. One possibility is that the higher baseline BMI of the
IMPACT group contributed to the elevated rate of incident diabetes. Specifically, this may have
led to an increase in the degree of insulin resistance and the prevalence of pre-diabetes in the
IMPACT group. Consequently, a higher percentage of patients in this arm would transition to
Table 2. Results of Cox proportional hazard regression models examining treatment group as a predictor of incident diabetes–alternative definitions of incident
diabetes.
Diabetes Outcome
Total Sample
(N = 119)
IMPACT
(n = 59)
Usual Care
(n = 60)
Treatment Group
(IMPACT vs. Usual Care)
Events (%) HR 95% CI p value
Any Diagnosis § 20 (16.8%) 13 (22.0%) 7 (11.7%) 1.75 0.69–4.46 .237
Fully-Adjusted ‡ 1.66 0.61–4.51 .319
Any Lab Value  33 (27.7%) 19 (32.2%) 14 (23.3%) 1.31 0.66–2.61 .446
Fully-Adjusted ‡ 1.11 0.54–2.28 .779
Any Medication Ϯ 11 (9.2%) 7 (11.9%) 4 (6.7%) 1.76 0.52–6.02 .366
Fully-Adjusted ‡ 1.82 0.38–8.67 .451
Note. N = 119. HR = hazard ratio. CI = confidence interval. ICD-9 = International Classification of Diseases-9th Revision. IMPACT = Improving Mood-Promoting
Access to Collaborative Treatment. HbA1c = Hemoglobin A1c
§ Defined as an ICD-9 code for diabetes.
‡ Adjusted for age, sex, race/ethnicity, hypertension, smoking status, and body mass index.
Defined as a fasting glucose value 126mg/dL OR an HbA1c value 8.0%.
Ϯ Defined as a prescription for diabetes medication (insulin or oral hypoglycemic medication).
https://doi.org/10.1371/journal.pone.0200248.t002
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diagnosed, clinical diabetes during the follow-up. The BMI-adjusted analyses provide partial
support for this notion, given that BMI was a significant predictor of incident diabetes, and
adjustment for BMI attenuated the hazard ratio. A second possibility is that IMPACT patients
had greater contact with the healthcare system due to the intervention and therefore, were more
likely to be referred for other health services during the 9-year follow-up period. As a result, this
group may have been followed more closely and had more opportunities for detection of new-
onset diabetes than the usual care group.
There are also three leading explanations for the null effect of collaborative depression care
on diabetes risk. The first is the older age of the sample. Because insulin resistance increases
with age [29], its severity in the IMPACT sample, despite the absence of diagnosed diabetes, was
likely high. In addition, there was a high prevalence of diabetes risk factors (e.g., BMI) in the
sample at baseline (see Table 1). Together, the older age and, therefore, severity of insulin resis-
tance of this cohort, in conjunction with its high baseline diabetes risk factors status, may have
overridden any effect of depression treatment on diabetes incidence. Nevertheless, whether or
not depression treatment alone lowers diabetes risk in middle-aged and younger adults is an
open question. Given the older age of our sample, many diabetes cases, perhaps especially those
that were depression related, likely developed prior to enrollment in the IMPACT Trial and
these patients are not included in our sample. The second is potential depression treatment
improvement in the usual care group. As Table 1 demonstrates, 57% and 17% of individuals in
the usual care arm received antidepressant medication and psychotherapy, respectively. It is
possible that without this relatively high level of depression treatment, depressive symptom
severity in this group may have worsened over time. Thus, due to a greater number of usual
care patients being treated for depression, group differences in depressive symptom improve-
ment, and subsequently, incident diabetes, were likely reduced. The third is the high rate of anti-
depressant exposure in both groups and the potential diabetogenic effect of these medications.
As noted in Table 1, 73% and 57% of the IMPACT and usual care groups, respectively, received
antidepressant medication during the intervention. Studies demonstrate that some antidepres-
sant medications are associated with and increased risk of type 2 diabetes through various
mechanisms, including appetite promotion and weight gain [30–32]. Taken together, increased
antidepressant medication use in both groups may have resulted in the lack of treatment group
differences in incident diabetes we observed. However, it should be noted that because other
studies demonstrate no effects or weight loss as a result of antidepressant use [33, 34], the cur-
rent literature linking antidepressant medication and diabetes appears to be inconclusive.
While our study is unique and begins to address an important public health topic, its find-
ings are preliminary and should be interpreted in light of the following limitations. First, our
analyses were observational in nature because the IMPACT trial was not designed to examine
our specific question. For example, randomization was not stratified by baseline diabetes, and
incident diabetes was not a pre-specified outcome. While patients without diabetes were
equally distributed across the treatment groups, and a strong theoretical rationale was present,
only a prospective randomized controlled trial specifically designed to test the study hypothe-
ses would allow for definitive conclusions to be drawn. Second, while we had a strong rationale
for using a higher cut point for HbA1c (8.0%) given the demographic and clinical characteris-
tics of our sample [14], an HbA1c cut point of> 6.5% is a more commonly accepted criterion
for diabetes diagnosis [13]. Thus, future studies may consider comparing our findings with
those using this and other criteria for HbA1c. Finally, our analyses were underpowered to fully
test the study question. Consequently, we consider our results to be preliminary and in need of
replication in future intervention studies.
This study begins to address a key clinical issue, as reducing the elevated diabetes risk of
depressed individuals is imperative, and begins to fill an important knowledge gap, as no study
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has examined the effect of depression treatment on incident clinical diabetes. Our findings
raise the possibility that depression treatment alone may be insufficient to reduce the excess
diabetes risk of depressed adults. Although our findings are preliminary, they remain valuable
for hypothesis generation and for informing the design of future intervention studies. The
main objective of these future trials will be to determine whether depression treatment lowers
diabetes risk and whether any treatment effects on diabetes outcomes are mediated by depres-
sion outcome or care variables. If on the other hand, these adequately-powered, well-designed
and executed studies determine that depression treatment does not lower diabetes risk, then
other approaches for reducing the elevated diabetes risk of depressed patients need to be iden-
tified. Specifically, if our results are replicated, it would suggest the need for an integrated biop-
sychosocial treatment program that simultaneously intervenes on depression and the putative
mechanisms underlying the depression-diabetes relationship in order to produce clinically
meaningful reductions in incident diabetes in this population.
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